Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review
- PMID: 36657243
- PMCID: PMC9804969
- DOI: 10.1016/j.jiph.2022.12.022
Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review
Abstract
Background: There is paucity of data describing the impact of COVID-19 pandemic on antimicrobial resistance. This review evaluated the changes in the rate of multidrug resistant gram negative and gram positive bacteria during the COVID-19 pandemic.
Methods: A search was conducted in PubMed, Science Direct, and Google Scholar databases to identify eligible studies. Studies that reported the impact of COVID-19 pandemic on carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta-lactamase inhibitor (ESBL)-producing Enterobacteriaceae, vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Pseudomonas aeruginosa (CPE) were selected. Studies published in English language from the start of COVID-19 pandemic to July 2022 were considered for inclusion.
Results: Thirty eligible studies were selected and most of them were from Italy (n = 8), Turkey (n = 3) and Brazil (n = 3). The results indicated changes in the rate of multidrug resistant bacteria, and the changes varied between the studies. Most studies (54.5%) reported increase in MRSA infection/colonization during the pandemic, and the increase ranged from 4.6 to 170.6%. Five studies (55.6%) reported a 6.8-65.1% increase in VRE infection/colonization during the pandemic. A 2.4-58.2% decrease in ESBL E. coli and a 1.8-13.3% reduction in ESBL Klebsiella pneumoniae was observed during the pandemic. For CRAB, most studies (58.3%) reported 1.5-621.6% increase in infection/colonization during the pandemic. Overall, studies showed increase in the rate of CRE infection/colonization during the pandemic. There was a reduction in carbapenem-resistant E. coli during COVID-19 pandemic, and an increase in carbapenem-resistant K. pneumoniae. Most studies (55.6%) showed 10.4 - 40.9% reduction in the rate of CRPA infection during the pandemic.
Conclusion: There is an increase in the rate of multidrug resistant gram positive and gram negative bacteria during the COVID-19 pandemic. However, the rate of ESBL-producing Enterobacteriaceae and CRPA has decrease during the pandemic. Both infection prevention and control strategies and antimicrobial stewardship should be strengthen to address the increasing rate of multidrug resistant gram positive and gram negative bacteria.
Keywords: Antimicrobial resistance; COVID-19 pandemic; Carbapenem-resistant enterobacteriaceae; Gram negative; Gram positive; Impact; MRSA; Vancomycin-resistant enterococci.
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Competing interests None declared.
Figures
Similar articles
-
Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis.Clin Microbiol Infect. 2023 Mar;29(3):302-309. doi: 10.1016/j.cmi.2022.12.006. Epub 2022 Dec 9. Clin Microbiol Infect. 2023. PMID: 36509377 Free PMC article.
-
A time series analysis approach to quantify change in antibiotic resistance and antibiotic consumption during COVID-19 epidemics: a multicentre cross-national ecological study on behalf of QUantifying change in Antibiotic Resistance, ANTibiotic use, and INfection control during COVID-19 Epidemics study project.Clin Microbiol Infect. 2025 Jun 16:S1198-743X(25)00296-4. doi: 10.1016/j.cmi.2025.06.009. Online ahead of print. Clin Microbiol Infect. 2025. PMID: 40516754
-
Nationwide surveillance of carbapenem-resistant Gram-negative pathogens in the Lebanese environment.Appl Environ Microbiol. 2025 Jul 23;91(7):e0193224. doi: 10.1128/aem.01932-24. Epub 2025 Jun 10. Appl Environ Microbiol. 2025. PMID: 40492734 Free PMC article.
-
Effects of screening strategies to detect carbapenem-resistant gram-negative bacteria: A systematic review.Am J Infect Control. 2022 Dec;50(12):1381-1388. doi: 10.1016/j.ajic.2022.02.018. Epub 2022 Feb 26. Am J Infect Control. 2022. PMID: 35227794
-
Carbapenem-Resistant Gram-Negative Bacterial Infections at a Tertiary Health Care Center in Nepal: An Observational Study.JNMA J Nepal Med Assoc. 2025 Jan;63(281):47-51. doi: 10.31729/jnma.8862. Epub 2025 Jan 31. JNMA J Nepal Med Assoc. 2025. PMID: 40655521 Free PMC article.
Cited by
-
Impact of SARS-CoV-2 Preventive Measures against Healthcare-Associated Infections from Antibiotic-Resistant ESKAPEE Pathogens: A Two-Center, Natural Quasi-Experimental Study in Greece.Antibiotics (Basel). 2023 Jun 22;12(7):1088. doi: 10.3390/antibiotics12071088. Antibiotics (Basel). 2023. PMID: 37508184 Free PMC article.
-
Impact of COVID-19 pandemic on antimicrobial resistance of Proteus mirabilis in a Brazilian hospital.Braz J Microbiol. 2025 Mar;56(1):499-510. doi: 10.1007/s42770-024-01568-8. Epub 2024 Dec 4. Braz J Microbiol. 2025. PMID: 39630218
-
The Prevalence of Alert Pathogens and Microbial Resistance Mechanisms: A Three-Year Retrospective Study in a General Hospital in Poland.Pathogens. 2023 Nov 28;12(12):1401. doi: 10.3390/pathogens12121401. Pathogens. 2023. PMID: 38133286 Free PMC article.
-
The Hidden Cost of COVID-19: Focus on Antimicrobial Resistance in Bloodstream Infections.Microorganisms. 2023 May 16;11(5):1299. doi: 10.3390/microorganisms11051299. Microorganisms. 2023. PMID: 37317274 Free PMC article. Review.
-
A scoping review of bacterial resistance among inpatients amidst the COVID-19 pandemic.J Glob Antimicrob Resist. 2024 Sep;38:49-65. doi: 10.1016/j.jgar.2024.05.010. Epub 2024 May 23. J Glob Antimicrob Resist. 2024. PMID: 38789083 Free PMC article.
References
-
- Centers for Disease Control and Prevention Antibiotic resistance threats in the United States, 2019. US Department of Health and Human Services. Cent Dis Control Prev. 2019
-
- Abubakar U., Tangiisuran B., Elnaem M.H., Sulaiman S.A., Khan F.U. Mortality and its predictors among hospitalized patients with infections due to extended spectrum beta-lactamase (ESBL) Enterobacteriaceae in Malaysia: a retrospective observational study. Future J Pharm Sci. 2022;8(1):1–8.
-
- O'Neill J. Tackling drug-resistant infections globally: final report and recommendations.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous